Canadian Hospital Using PerkinElmer Tools for Newborn Screening Program | GenomeWeb
NEW YORK (GenomeWeb News) — Capital Health of Alberta is using PerkinElmer’s mass spectrometers, reagents, and software in a newborn screening program, PerkinElmer said today.

Under a multi-year agreement, the Edmonton-based Capital Health has bought PerkinElmer’s tandem mass spectrometry systems, reagent kits, and its Specimen Gate software to screen newborns for 17 hereditary metabolic disorders, including cystic fibrosis.  

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.